Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
This is a 100% increase over the number of companies cited in the previous quarter.
The citations in the county include:
- Written procedures have not been developed for the surveillance and reporting to FDA of post marketing adverse drug experiences.
- A postmarketing 15-day Alert report based upon scientific literature was not accompanied by a copy of the published article.
- You did not develop an FSVP.
Both companies cited were involved in either Drugs or Food and Cosmetics sectors.
Both companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Ambrosia Parade Restaurant, LLC | Food and Cosmetics | 02/02/2024 | Develop FSVP |
Ambrosia Parade Restaurant, LLC | Food and Cosmetics | 02/02/2024 | Document review entity's hazard analysis |
Ambrosia Parade Restaurant, LLC | Food and Cosmetics | 02/02/2024 | Evaluation - performance, risk |
Ambrosia Parade Restaurant, LLC | Food and Cosmetics | 02/02/2024 | Supplier approval - document |
Ambrosia Parade Restaurant, LLC | Food and Cosmetics | 02/02/2024 | Verification activity - appropriate |
Tris Pharma, Inc. | Drugs | 03/08/2024 | Failure to develop written procedures |
Tris Pharma, Inc. | Drugs | 03/08/2024 | Failure to submit scientific article |